Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 8, 2009, Pages 2339-2342

  Dombernowsky, Sarah Louise ^a   Weischer, Maren ^a,d   Freiberg, Jacob Johannes ^a   Bojesen, Stig Egil ^a,c   Tybjærg Hansen, Anne ^b,c   Nordestgaard, Børge Grønne ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE SEQUENCE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; OVARY CANCER; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 68949084967     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0447     Document Type: Article

References (24)

1. Gerdes AM, Cruger DG, Thomassen M, Kruse TA. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clin Genet 2006;69:171-8.
2. Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays 2000;22:728-37.
3. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997;272:31941-4.
4. Domb ernowsky SL, Weischer M, Allin KH, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Risk of cancer by ATM missense mutations in the general population. J Clin Oncol 2008;26:3057-62.
5. WeischerM,BojesenSE,Tybjaerg-HansenA,AxelssonCK,Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100-delC. J Clin Oncol 2007;25:57-63.
6. Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Integrin β3 Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst 2003;95:1150-7.
7. Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. No association of breast cancer risk with integrin β3 (ITGB3) Leu33Pro genotype. Br J Cancer 2005;93:167-71.
8. Auranen A, Spurdle AB, Chen X, et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer 2003;103:427-30.
9. Auranen A, Song H, Waterfall C, et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 2005;117:611-8.
10. Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 2006;98:1382-96.
11. Cox DG, Hankinson SE, Hunter DJ. No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:1353-4.
12. Dunning AM, Chiano M, Smith NR, et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet 1997;6:285-9.
13. Durocher F, Shattuck-Eidens D, McClure M, et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet 1996;5:835-42.
14. Freedman ML, Penney KL, Stram DO, et al. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort. Hum Mol Genet 2004;13:2431-41.
15. Garcia-Closas M, Egan KM, NewcombP A, et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 2006;119:376-88.
16. Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000;26:362-4.
17. Hughes DJ, Ginolhac SM, Coupier I, et al. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev 2005;14:265-7.
18. Janezic SA, Ziogas A, Krumroy LM, et al. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Mol Genet 1999;8:889-97.
19. Menzel HJ, Sarmanova J, Soucek P, et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 2004;90:1989-94.
20. Ramus SJ, Vierkant RA, Johnatty SE, et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 2008;123:380-8.
21. Seymour IJ, Casadei S, Zampiga V, et al. Disease family history and modification of breast cancer risk in common BRCA2 variants. Oncol Rep 2008;19:783-6.
22. Soucek P, Borovanova T, Pohlreich P, Kleibl Z, Novotny J. Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study. Breast Cancer Res Treat 2007;103:219-24.
23. Spurdle AB, Hopper JL, Chen X, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev 2002;11:413-6.
24. Wenham RM, Schildkraut JM, McLean K, et al. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res 2003;9:4396-403.